Xie R, Li A H, Ji X D, Melman N, Olah M E, Stiles G L, Jacobson K A
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.
J Med Chem. 1999 Oct 7;42(20):4232-8. doi: 10.1021/jm990234x.
A(3) adenosine receptor antagonists are sought for their potential antiinflammatory, antiasthmatic, and antiischemic properties. We have found that 3,5-diacyl-1,2,4-trialkyl-6-phenylpyridinium derivatives constitute a novel class of selective A(3) adenosine receptor antagonists. The structure-activity relationships of this class of antagonists, incorporating the 3-thioester, have been explored. The most potent analogue in this group was 2, 4-diethyl-1-methyl-3-(ethylsulfanylcarbonyl)-5-ethyloxycarbonyl -6-phe nylpyridinium iodide (11), which had an equilibrium inhibition constant (K(i)) value of 219 nM at human A(3) receptors (binding of [(125)I]AB-MECA (N(6)-(4-amino-3-iodobenzyl)-5'-N-methylcarbamoyladenosine)) expressed in Chinese hamster ovary (CHO) cells and >10 microM at rat brain A(1) and A(2A) receptors and at recombinant human A(2B) receptors. Compound 11 could be generated through oxidation of the corresponding 3,5-diacyl-1,2,4-trialkyl-6-phenyl-1,4-dihydropyridine, 24, with iodine or in the presence of rat brain homogenates. A 6-cyclopentyl analogue was shown to increase affinity at human A(3) receptors upon oxidation from the 1-methyl-1,4-dihydropyridine analogue, 25, to the corresponding pyridinium derivative, 23 (K(i) 695 nM), suggesting a prodrug scheme. Homologation of the N-methylpyridinium derivatives to N-ethyl and N-propyl at the 1-position caused a progressive reduction in the affinity at A(3) receptors. Modifications of the alkyl groups at the 2-, 3-, 4-, and 5-positions failed to improve potency in binding at A(3) receptors. The pyridinium antagonists are not as potent as other recently reported, selective A(3) receptor antagonists; however, they display uniquely high water solubility (43 mM for 11). Compound 11 antagonized the inhibition of adenylate cyclase elicited by IB-MECA in CHO cells expressing the human A(3) adenosine receptor, with a K(B) value of 399 nM, and did not act as an agonist, demonstrating that the pyridinium salts are pure antagonists.
人们一直在寻找具有潜在抗炎、抗哮喘和抗缺血特性的A(3)腺苷受体拮抗剂。我们发现3,5 - 二酰基 - 1,2,4 - 三烷基 - 6 - 苯基吡啶鎓衍生物构成了一类新型的选择性A(3)腺苷受体拮抗剂。已经探索了这类含有3 - 硫酯的拮抗剂的构效关系。该组中最有效的类似物是2,4 - 二乙基 - 1 - 甲基 - 3 - (乙硫基羰基) - 5 - 乙氧羰基 - 6 - 苯基吡啶鎓碘化物(11),其在表达于人卵巢细胞(CHO)中的人A(3)受体处的平衡抑制常数(K(i))值为219 nM([(125)I]AB - MECA(N(6)-(4 - 氨基 - 3 - 碘苄基)-5'-N - 甲基氨甲酰腺苷)的结合),而在大鼠脑A(1)和A(2A)受体以及重组人A(2B)受体处大于10 μM。化合物11可以通过相应的3,5 - 二酰基 - 1,2,4 - 三烷基 - 6 - 苯基 - 1,4 - 二氢吡啶24用碘氧化或在大鼠脑匀浆存在下生成。一种6 - 环戊基类似物从1 - 甲基 - 1,4 - 二氢吡啶类似物25氧化为相应的吡啶鎓衍生物23(K(i) 695 nM)时,显示出对人A(3)受体亲和力增加,提示一种前药方案。1 - 位的N - 甲基吡啶鎓衍生物同系化为N - 乙基和N - 丙基导致对A(3)受体的亲和力逐渐降低。2 -、3 -、4 - 和5 - 位烷基的修饰未能提高在A(3)受体结合的效力。吡啶鎓拮抗剂不如其他最近报道的选择性A(3)受体拮抗剂有效;然而,它们表现出独特的高水溶性(11为43 mM)。化合物11拮抗了在表达人A(3)腺苷受体的CHO细胞中由IB - MECA引起的腺苷酸环化酶抑制,K(B)值为399 nM,并且不作为激动剂,表明吡啶鎓盐是纯拮抗剂。